DOCSLIB.ORG

Treatment of Alcohol Use Disorders New Options for Better Outcomes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment of Alcohol Use Disorders New Options for Better Outcomes Treatment of Alcohol Use Disorders New Options for Better Outcomes Wim van den Brink, MD PhD Amsterdam University Medical Centers, location AMC Amsterdam, The Netherlands Nordic Reform Conference 2019 Oslo, 20 September 2019 Disclosure Interest Name of organization Grants Alkermes Lundbeck, Merck Serono, Eli Lilly, Indivior, Pfizer, Honoraria Angelini Lundbeck, Merck Serono, Indivior, Mundipharma, Advisory Board/Consultant D&A Pharma, Bioproject, Novartis, Kinnov Therapeutics, Opiant Pharmaceuticals, Takeda Content • Addiction a treatable brain disorder • Many new neurobiological and psychological treatments • New treatment goals • Role of substitution treatment • Compliance, polypharmacy, and precision medicine • New paradigms • Conclusions Addiction a Treatable Brain Disorder Heritability estimates Heritability estimates for alcohol dependence, nicotine dependence, cannabis and other illicit drug use disorders across samples of twins Type of dependence Heritability 80 70 60 Alcohol 50–70% 50 40 Nicotine 50–75% 30 Heritability 20 10 (% of total variance) Cannabis 35–75% 0 Cocaine 35–80% Dutch Virginia Finnish twins Colorado twins twins Minnesotatwins twins Australiantwins Vietnamtwins era Heroin 40–60% Alcoholism Cannabis use disorder Nicotine dependence Any illicit drug use disorder Agrawal & Lynskey. Addiction 2008;103(7):1069–1081 Alcoholism Phenotype Social Alcoholism support spectrum Liability alcoholism Insight- oriented psychotherapy Conditioning Attentional bias Drug CBT Endophenotype Low alcohol Use Reward response Disinhibition deficiency Medication Conflict etc Neuromodulation monitoring Candidate genes Pharmaco- OPRM1 genetics DRD1 COMT GRIN2B GABRA6 Genotype DRD2 Gene SERT MAOA therapy CNR1 Ooteman et al (2006) adapted from: HTR1B Gottesman & Gould. Am J Psychiatry GABRB2 2003;160:636–645 GABRG2 Neurobiology of addiction Function Brain structures Neurotransmitters Naive Ventral tegmental area (VTA) Endorphins (μ-receptors) Reward deficiency Experimenting Nucleus accumbens (NAc) Dopamine moderate use Disinhibition DLPFC Noradrenalin, 5-HT Impulsivity ACC GABA, glutamate Binging NAc (ventral striatum) Dynorphins (κ-receptors) Abuse Conditioning Amygdala, Hippocampus Dopamine Craving Thalamus CRH Prefrontal cortex (OFC, ACC) Glutamate Attentional bias/ OFC Dependence Dopamine salience VMPFC (craving) Putamen, Nc caudatus Dopamine Habit formation (dorsal striatum) Addiction (compulsive use) Noradrenalin, CRH Withdrawal Locus coeruleus Glutamate Van Ree. 2002; de Vries & Schippenberg. 2002; Kreek et al. 2002; 7 Van den Brink. 2006; Volkow. 2004; Koob & Volkow. 2010 Alcoholism Fenotype Alcoholism spectrum Liability alcoholism IRISA: Hyperactive Conditioning Attentional bias Motivational system Endofenotype Deficient Reward Salience Disinhibition deficiency I Cognitive control system Conflict etc monitoring Candidate genes OPRM1 DRD1 COMT GRIN2B GABRA6 Genotype DRD2 SERT MAOA CNR1 Ooteman et al (2006) adapted from: HTR1B Gottesman & Gould. Am J Psychiatry GABRB2 2003;160:636–645 GABRG2 Brain Structures and Functions in Addiction 2006 Reward attentional bias cue-reactivity craving - deficient cognitive control - relapse Repeated reward Detection threshold Inhibition Attentional bias Cue-reactivity Craving Relapse Drug-related stimulus Conflict registration Neurobiology of addiction Function Brain structures Neurotransmitters Naive Ventral tegmental area (VTA) Endorphins (μ-receptors) Reward deficiency Experimenting Nucleus accumbens (NAc) Dopamine moderate use Disinhibition DLPFC Noradrenalin, 5-HT Impulsivity ACC GABA, glutamate Binging NAc (ventral striatum) Dynorphins (κ-receptors) Abuse Conditioning Amygdala Dopamine Craving Thalamus CRH Prefrontal cortex (OFC, ACC) Glutamate Attentional bias/ OFC Dependence Dopamine salience VMPFC (craving) Putamen, Nc caudatus Dopamine Habit formation (dorsal striatum) Addiction (compulsive use) Noradrenalin, CRH Withdrawal Locus coeruleus Glutamate Van Ree. 2002; de Vries & Schippenberg. 2002; Kreek et al. 2002; 11 Van den Brink. 2006; Volkow. 2004; Koob & Volkow. 2010 From reward to relief and from impulsive to compulsive impulsive compulsive Adapted from Heilig et al., 2010 Reward attentional bias cue-reactivity craving - deficient cognitive control - relapse Repeated reward Detection threshold Inhibition Attentional bias Cue-reactivity Craving Relapse Drug-related stimulus Conflict registration Reward attentional bias cue-reactivity craving - deficient cognitive control - relapse Repeated reward Detection threshold Inhibition Attentional bias Cue-reactivity Craving Relapse Drug-related stimulus STRESS WITHDRAWAL Conflict registration Conceptual Treatment Models Pharmacological Tx Model for Pharmacotherapy of Addiction Repeated reward Antagonist Agonis Detection threshold Inhibition t Cognitiv Attentional bias Cue-reactivity Craving e Relapse Anti-cra enhanc ving er medicati on Stress Conflict registration Drug-related stimulus Anti-stress medication 16 Pharmacotherapy Alcohol Use Disorder • HD Baclofen? Repeated reward • Sodium Oxybate? • Gabapentin? • Disulfiram • C H OH (alcohol) Antagonist • Naltrexone 2 5 • Nalmefene Agonis Detection threshold Inhibition t Cognitiv Attentional bias Cue-reactivity Craving e Relapse Anti-cra enhanc ving • Modafinil?er drug Conflict •registration LSD/Psilocybin? Stress • Acamprosate Drug-related stimulus • Topiramate? • LD Baclofen doxazosine • Varenicline?? Problems with potentially new medications • Many of the new medications are already out of patent • Testing new compounds for AUDs is risky for pharmaceutical industry • Not very likely that all these promising medications will be EMA/FDA registered • New role for professional, patient and political organisations • Non-registered medications with “enough” scientific support in guidelines! • Reimburse off-label prescriptions by specialist as off-label prescriptions! • Monitor the use, outcomes and potential18 adverse events! Conceptual Treatment Models Psychological Tx JSAD, 2011 20 ACER, 2011 “Change talk” vermindert activatie tijdens cue-reactivity regio’s tijdens kleine dosis voorkeursdrank en leidt tot minder craving 21 Model for Psychotherapy of Addiction Repeated reward Counterconditioni ng CM Detection threshold Inhibition CRA MET Attentional bias Cue-reactivity CET Craving Working Relapse (+DCS) Memory Act Training MBRP Stress EMDR? Conflict registration Drug-related stimulus CBT Mindfulness 22 Conclusions and remaining issues • Many pharmacological interventions for alcohol (nicotine and opioid) dependence • Very few pharmacological interventions for stimulant and cannabis dependence • Many psychological interventions for all addictions • BUT • Do patients and therapists want all these treatments? * abstinence vs. reduced/controlled drinking * agonists (often liked by patients) vs. antagonists (often liked by therapists) * change vs. acceptance of craving • How effective are these interventions? * compliance, polypharmacy, precision medicine • New paradigms ? New Treatment Goals Treatment gap in alcohol dependence (%) Treatment gap* Treatment Alcohol abuse and dependence have the widest treatment gap among all mental disorders – less than 10% of European patients with alcohol abuse and dependence are treated Kohn et al. Bull World Health Organ * Treatment gap=difference between number needing MH Tx and number receiving MH Tx 2004;82:858–866 Reasons for not seeking AD treatment Not ready to stop using Cost/insurance barriers Social stigma Access Did not think needed treatment/ thought could handle without treatment Did not know where to go for treatment Did not have time Treatment would not help Other barriers Percent SAMHSA 2007, National Survey on Drug Use and Health (NSDUH) Treatment Preference (UK & Canada) UK survey of patients with alcohol problems Canadian study of patients with chronic (n=742) alcoholism (n=106) Heather et al. Alcohol Alcohol 2010;45(2):128–135 Hodgins et al. Addict Behav 1997;22(2):247–255 Need for alcohol reduction intervention Effective Pharmacotherapy Alcohol Dependence Treatment Goal 1st Choice 2nd Choice 3rd Choice Acamprosate Disulfiram Baclofen? (NNT=11) (NNT=25; NS)* Sodium Oxybate? Abstinence Naltrexone?? (NNT=20) Gabapentin? Reduced Drinking Naltrexone# Modafinil?? (NNT=11) Topiramate? Varenicline? Nalmefene? Doxasozine?? * no supervision First choice registered reduced drinking medication? # off-label (and many 2nd and 3rd choice medications) treatment: months 1-4 post-treatment follow-up months 5-16 Witkiewitz et al., in press (Addiction): sustainability 29of reduced drinking independent of baseline severity Role of Substitution Treatment Sunday 17 December 2017 Western societies will 'give up alcohol' within a generation, leading drugs scientist claims Professor David Nutt, a former government drugs advisor teaching at Imperial College, said “alcosynth” will mimic the popular effects of alcohol – without the sickness and throbbing headache commonly experienced the following day. Will “alcosynth” look like GHB? 31 Position papers 2012 Requirements: * Agonist (effect) * Oral use with longer effect * Low toxicity Safety measures * Tx setting: specialist+support * Combine with psychosocial 2015 32 * Define outcomes * No effect on polydrug use Effective Pharmacotherapy Alcohol Dependence Treatment Goal 1st Choice 2nd Choice 3rd Choice Acamprosate Disulfiram Baclofen? (NNT=11) (NNT=25; NS)* Sodium Oxybate? Abstinence Naltrexone?? (NNT=20) Gabapentin? Reduced Drinking Naltrexone# Modafinil?? (NNT=11) Topiramate? Varenicline? Nalmefene?
Load more

Recommended publications
  • A Quantitative Analysis of the Value-Enhancing Effects of Nicotine
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Theses, Dissertations, and Student Research: Psychology, Department of Department of Psychology Fall 12-4-2014 A Quantitative Analysis of the Value-Enhancing Effects of Nicotine, Bupropion, and Varenicline in Male and Female Rats Scott aB rrett University of Nebraska-Lincoln, [email protected] Follow this and additional works at: http://digitalcommons.unl.edu/psychdiss Part of the Behavioral Neurobiology Commons, Biological Psychology Commons, Experimental Analysis of Behavior Commons, and the Pharmacology Commons Barrett, Scott, "A Quantitative Analysis of the Value-Enhancing Effects of Nicotine, Bupropion, and Varenicline in Male and Female Rats" (2014). Theses, Dissertations, and Student Research: Department of Psychology. 70. http://digitalcommons.unl.edu/psychdiss/70 This Article is brought to you for free and open access by the Psychology, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Theses, Dissertations, and Student Research: Department of Psychology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. A QUANTITATIVE ANALYSIS OF THE VALUE-ENHANCING EFFECTS OF NICOTINE, BUPROPION, AND VARENICLINE IN MALE AND FEMALE RATS by Scott Taylor Barrett A DISSERTATION Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Doctor of Philosophy Major: Psychology Under the Supervision of Professor Rick A. Bevins Lincoln, Nebraska November, 2014 A QUANTITATIVE ANALYSIS OF THE VALUE-ENHANCING EFFECTS OF NICOTINE, BUPROPION, AND VARENICLINE IN MALE AND FEMALE RATS Scott Taylor Barrett, Ph.D. University of Nebraska, 2014 Advisor: Rick A. Bevins Smoking and tobacco dependence are serious health concerns in the United States and globally.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Specialized Rehabilitation Services for Military Service Members And
    Psychopharmacologic Approaches to Affective Disorders and Executive Dysfunction after Brain Injury Mel B. Glenn, M.D. National Medical Director, NeuroRestorative Medical Director, NeuroRestorative Massachusetts & Rhode Island Audio Check To ensure that you can hear the presentation, please take a moment to double check your audio settings. Go to the Audio tab in your GoToWebinar dashboard. • If you have selected phone call, make sure you’re dialed into the conference number. • If you are dialed in but cannot hear, try hanging up and calling back in. • If you are using only computer audio, check that your device isn’t muted. • If you’re using listening devices such as headsets, double check they are plugged in/turned on. 2 NeuroRestorative’s COVID-19 Response We are committed to protecting the health and safety of the individuals we serve, our staff, and the community. Our services are considered essential, and we are taking precautions to minimize disruption to services and keep those in our care and our team members safe. In some programs, that has meant innovating our service delivery model through Interactive Telehealth Services. We provide Interactive Telehealth Services throughout the country as an alternative to in- person services. Through Interactive Telehealth Services, we deliver the same high-quality supports as we would in-person, but in an interactive, virtual format that is HIPAA compliant and recognized by most healthcare plans and carriers. You can learn more about our COVID-19 prevention and response plan at our Update Center by visiting neurorestorative.com. 3 Disclosures • Advisor, Traumatic Brain Injury Model Systems grant, National Institute on Disability, Independent Living, and Rehabilitation Research, U.S.
    [Show full text]
  • Varenicline Criteria for Prescribing
    Varenicline Criteria Varenicline Criteria for Prescribing VA Center for Medication Safety, Tobacco Use Cessation Technical Advisory Group, Public Health Strategic Healthcare Group, VA Pharmacy Benefits Management Services, VISN Pharmacist Executives, and Medical Advisory Panel May 2008; Updated June 2008; Updated August 2008; Updated February 2010; Updated July 2011 The following recommendations are based on current medical evidence and expert opinion from clinicians. The content of the document is dynamic and will be revised as new clinical data becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. The clinician should utilize this guidance and interpret it in the clinical context of individual patient situations. Introduction: Varenicline is a second-line medication for smoking cessation in the VA health care system and should be used only for those patients who have failed an appropriate trial of nicotine replacement therapy, bupropion, or combination therapy (Combination Therapy Recommendations)(or medical contraindication to these medications) within the past year. In rare instances, varenicline has been associated with violent thoughts, intent or actions toward oneself or others. Prior to starting varenicline, patients should be screened for feelings of hopelessness, which may increase the risk of suicide once the medication is started. Patients should also be screened for current suicidal ideation or intent as well as a history of past suicide attempts. The recommended screening questions for suicide/violence risk are in Box 1, below: Patients who are positive on any of the screening questions require further evaluation by a mental health professional.
    [Show full text]
  • The Effect of Sazetidine-A and Other Nicotinic Ligands on Nicotine Controlled Goal-Tracking in Female and Male Rats
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Kentucky University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Publications Pharmaceutical Sciences 2-2017 The Effect of Sazetidine-A and Other Nicotinic Ligands on Nicotine Controlled Goal-Tracking in Female and Male Rats S. Charntikov University of New Hampshire A. M. Falco University of Nebraska - Lincoln K. Fink University of Nebraska - Lincoln Linda P. Dwoskin University of Kentucky, [email protected] See next page for additional authors Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Follow this and additional works at: https://uknowledge.uky.edu/ps_facpub Part of the Chemicals and Drugs Commons, Neuroscience and Neurobiology Commons, and the Pharmacy and Pharmaceutical Sciences Commons Authors S. Charntikov, A. M. Falco, K. Fink, Linda P. Dwoskin, and R. A. Bevins The Effect of Sazetidine-A and Other Nicotinic Ligands on Nicotine Controlled Goal- Tracking in Female and Male Rats Notes/Citation Information Published in Neuropharmacology, v. 113, part A, p. 354-366. © 2016 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC‐BY‐NC‐ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. The document available for download is the author's post-peer-review final draft of the article. Digital Object Identifier (DOI) https://doi.org/10.1016/j.neuropharm.2016.10.014 This article is available at UKnowledge: https://uknowledge.uky.edu/ps_facpub/128 HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Neuropharmacology Manuscript Author .
    [Show full text]
  • Nicotinic Acetylcholine Receptors
    nAChR Nicotinic acetylcholine receptors nAChRs (nicotinic acetylcholine receptors) are neuron receptor proteins that signal for muscular contraction upon a chemical stimulus. They are cholinergic receptors that form ligand-gated ion channels in the plasma membranes of certain neurons and on the presynaptic and postsynaptic sides of theneuromuscular junction. Nicotinic acetylcholine receptors are the best-studied of the ionotropic receptors. Like the other type of acetylcholine receptor-the muscarinic acetylcholine receptor (mAChR)-the nAChR is triggered by the binding of the neurotransmitter acetylcholine (ACh). Just as muscarinic receptors are named such because they are also activated by muscarine, nicotinic receptors can be opened not only by acetylcholine but also by nicotine —hence the name "nicotinic". www.MedChemExpress.com 1 nAChR Inhibitors & Modulators (+)-Sparteine (-)-(S)-B-973B Cat. No.: HY-W008350 Cat. No.: HY-114269 Bioactivity: (+)-Sparteine is a natural alkaloid acting as a ganglionic Bioactivity: (-)-(S)-B-973B is a potent allosteric agonist and positive blocking agent. (+)-Sparteine competitively blocks nicotinic allosteric modulator of α7 nAChR, with antinociceptive ACh receptor in the neurons. activity [1]. Purity: 98.0% Purity: 99.93% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in Water, Size: 10mM x 1mL in DMSO, 100 mg 5 mg, 10 mg, 50 mg, 100 mg (±)-Epibatidine A-867744 (CMI 545) Cat. No.: HY-101078 Cat. No.: HY-12149 Bioactivity: (±)-Epibatidine is a nicotinic agonist. (±)-Epibatidine is a Bioactivity: A-867744 is a positive allosteric modulator of α7 nAChRs (IC50 neuronal nAChR agonist. values are 0.98 and 1.12 μM for human and rat α7 receptor ACh-evoked currents respectively, in X.
    [Show full text]
  • Rationale, Pharmacology and Clinical Efficacy of Partial Agonists of A4b2
    Opinion TRENDS in Pharmacological Sciences Vol.28 No.7 Rationale, pharmacology and clinical efficacy of partial agonists of a4b2 nACh receptors for smoking cessation Hans Rollema1, Jotham W. Coe2, Leslie K. Chambers1, Raymond S. Hurst1, Stephen M. Stahl4 and Kathryn E. Williams3 1 Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA 2 Department of Chemistry, Pfizer Global Research and Development, Groton, CT 06340, USA 3 Department of Clinical Development, Pfizer Global Research and Development, Groton, CT 06340, USA 4 Department of Psychiatry, University of California at San Diego, 1930 Palomar Point Way, Suite 103 Carlsbad, CA 92008, USA Most smokers repeatedly fail in their attempts to stop [7–9]. Cigarettes are particularly addictive because they smoking because of the addictive nature of the nicotine are readily available and are extremely efficient at deliver- in tobacco products. Nicotine dependence is probably ing the neuroactive components of tobacco to the brain. In mediated through the activation of multiple subtypes essence, cigarettes provide, with each inhalation, indivi- of neuronal nicotinic acetylcholine receptor (nAChR), dualized control over the amount and frequency of nicotine among which the mesolimbic a4b2 subtype has a pivotal that is delivered to the brain and, thus, over mesolimbic role. Here, we discuss the rationale for and the design of dopamine (DA) neurotransmission – a crucial element of a4b2 nAChR partial agonists as novel treatments for the response to addictive substances. The rapid and tran- tobacco addiction. Such agents are expected to exhibit sient increases in DA release in the nucleus accumbens a dual action by sufficiently stimulating a4b2-nAChR- that inhaled nicotine produces will initiate and sustain mediated dopamine release to reduce craving when compulsive substance-seeking behavior and drug depen- quitting and by inhibiting nicotine reinforcement when dence in humans, as described for other drugs of abuse.
    [Show full text]
  • Discriminative Stimulus Effects of Mecamylamine and Nicotine In
    Pharmacology, Biochemistry and Behavior 179 (2019) 27–33 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms T ⁎ Colin S. Cunningham, Megan J. Moerke, Lance R. McMahon Department of Pharmacodynamics, The University of Florida, Gainesville, FL, USA ABSTRACT Mecamylamine is a non-competitive nicotinic acetylcholine receptor (nAChR) antagonist that has been prescribed for hypertension and as an off-label smoking cessation aid. Here, we examined pharmacological mechanisms underlying the interoceptive effects (i.e., discriminative stimulus effects) of mecamylamine (5.6 mg/ kg s.c.) and compared the effects of nAChR antagonists in this discrimination assay to their capacity to block a nicotine discriminative stimulus (1.78 mg/kg s.c.) in rhesus monkeys. Central (pempidine) and peripherally restricted nAChR antagonists (pentolinium and chlorisondamine) dose-dependently substituted for the me- camylamine discriminative stimulus in the following rank order potency (pentolinium > pempidine > chlorisondamine > mecamylamine). In contrast, at equi- effective doses based on substitution for mecamylamine, only mecamylamine antagonized the discriminative stimulus effects of nicotine, i.e., pentolinium, chlor- isondamine, and pempidine did not. NMDA receptor antagonists produced dose-dependent substitution for mecamylamine with the following rank order potency (MK-801 > phencyclidine > ketamine). In contrast, behaviorally active doses of smoking cessation aids including nAChR agonists (nicotine, varenicline, and cytisine), the smoking cessation aid and antidepressant bupropion, and the benzodiazepine midazolam did not substitute for the discriminative stimulus effects of mecamylamine. These data suggest that peripheral nAChRs and NMDA receptors may contribute to the interoceptive stimulus effects produced by mecamylamine.
    [Show full text]
  • Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys
    1521-0103/366/2/397–409$35.00 https://doi.org/10.1124/jpet.118.248070 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:397–409, August 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys Sarah L. Withey,1 Michelle R. Doyle,1,2 Jack Bergman, and Rajeev I. Desai Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts Received January 27, 2018; accepted May 17, 2018 ABSTRACT Evidence suggests that the a4b2, but not the a7, subtype of the except for lobeline, the nicotinic agonists produced either full nicotinic acetylcholine receptor (nAChR) plays a key role in [(1)-epibatidine, (2)-epibatidine, and nicotine] or partial (vare- Downloaded from mediating the behavioral effects of nicotine and related drugs. nicline, cytisine, anabaseine, and isoarecolone) substitution for However, the importance of other nAChR subtypes remains (1)-epibatidine. In interaction studies with antagonists differing unclear. The present studies were conducted to examine the in selectivity, (1)-epibatidine discrimination was substan- involvement of nAChR subtypes by determining the effects of tively antagonized by mecamylamine, slightly attenuated selected nicotinic agonists and antagonists in squirrel monkeys by hexamethonium (peripherally restricted) or dihydro- b a either 1) responding for food reinforcement or 2) discriminating the -erythroidine, and not altered by methyllycaconitine ( 7 jpet.aspetjournals.org nicotinic agonist (1)-epibatidine (0.001 mg/kg) from vehicle. In selective). Varenicline and cytisine enhanced (1)-epibati- food-reinforcement studies, nicotine, (1)-epibatidine, varenicline dine’s discriminative-stimulus effects.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Chemical-Scale Studies of G Protein-Coupled Receptors And
    112 Chapter 5: An unusual pattern of ligand-receptor interactions for the α7 nicotinic acetylcholine receptor, with implications for the binding of varenicline* 5.1 Abstract The α7 nicotinic acetylcholine receptor shows broad pharmacology, complicating the development of subtype-specific nicotinic receptor agonists. Here we use unnatural amino acid mutagenesis to characterize binding to α7 by the smoking cessation drug varenicline (Chantix), an α4β2-targeted agonist that shows full efficacy and modest potency at the α7 receptor. We find that unlike binding to its target receptor, varenicline does not form a cation-π interaction with TrpB, further supporting a unique binding mode for the cationic amine of nicotinic agonists at the α7 receptor. We also evaluate binding to the complementary face of the receptor’s binding site by varenicline, the endogenous agonist acetylcholine, and the potent nicotine analog epibatidine. Interestingly, we find no evidence for functionally significant interactions involving backbone NH and CO groups thought to bind the canonical agonist hydrogen bond acceptor of the nicotinic pharmacophore, perhaps reflecting a lesser importance of this pharmacophore element for α7 binding. We also show that the Trp55 and Leu119 side chains of the binding site’s complementary face are important for the binding of the larger agonists epibatidine and varenicline, but dispensable for binding of the smaller, endogenous agonist acetylcholine. *This chapter is adapted from: Van Arnam, E. B., Blythe, E. E., Lester, H. A., and Dougherty, D. A. An unusual pattern of ligand-receptor interactions for the α7 nicotinic acetylcholine receptor, with implications for the binding of varenicline. Mol Pharmacol (2013) 84, 201-207.
    [Show full text]
  • Effectiveness of Coadministration of Varenicline, Bupropion, and Serotonin Reuptake Inhibitors in a Smoking Cessation Program in the Real-Life Setting
    NicotineNicotine & Tobacco & TobaccoResearch Research Advance Access published November 5, 2012 Brief Report Effectiveness of Coadministration of Varenicline, Bupropion, and Serotonin Reuptake Inhibitors in a Smoking Cessation Program in the Real-Life Setting Jaqueline S. Issa, M.D., Ph.D.,1 Tania Ogawa Abe, M.D.,1 Simone Moura, M.D.,1 Paulo C. J. L. Santos, Ph.D.,2 & Alexandre C. Pereira, M.D., Ph.D.2 Downloaded from 1Smoking Cessation Program Department, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil. 2Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil. Corresponding Author: Jaqueline S. Issa, M.D., Ph.D. Heart Institute, University of Sao Paulo Medical School, Rua Dr. Eneas de Carvalho Aguiar 44, 1 andar Bloco2, CEP, Sao Paulo 05403-000, Brazil. Telephone: +0-55-11-2661-5698; Fax: (0 55 11) 2661 5592; http://ntr.oxfordjournals.org/ E-mail: [email protected] Received April 24, 2012; accepted September 21, 2012 Conclusions: Our results suggest that adjuvant treatment to Abstract varenicline therapy may be associated with improved success Introduction: Varenicline has a significant impact on the ability in smoking cessation, especially in patients with nicotine with- at Universidade de São Paulo on November 6, 2012 to quit smoking. However, patients may have side effects similar drawal symptoms. These results should be tested in randomized to nicotine withdrawal symptoms. The aim of this study was to controlled trials. evaluate the effectiveness of varenicline in monotherapy or in combined therapy with bupropion and/or serotonin reuptake inhibitors (SRIs) in a specific cardiovascular smoking cessation Introduction service.
    [Show full text]